Adipose tissue dysfunction is a key determinant of obesity-associated metabolic complications. Obesity increases the risk of type 2 diabetes (T2D) and is associated with metabolic abnormalities such as insulin resistance (IR), dyslipidemia, non-alcoholic fatty liver disease (NAFLD), hypertension, and cardiovascular disease. White adipose tissue (WAT) plays a critical role in energy homeostasis, expanding through hypertrophy (increase in adipocyte size) and hyperplasia (increase in number). In metabolically unhealthy obesity, the storage capacity of subcutaneous adipose tissue (SAT) is limited, leading to ectopic lipid accumulation in organs like the liver, skeletal muscle, and heart, a process known as lipotoxicity. This results in local inflammation and systemic IR. Excessive ectopic lipid accumulation triggers chronic low-grade inflammation, which exacerbates IR and T2D. In obesity, "healthy" WAT expansion is achieved through adipocyte hyperplasia, while hypertrophy promotes metabolic complications. Adipose tissue dysfunction is linked to impaired adipogenesis, inflammation, and ectopic lipid deposition. In obesity, the expansion of adipose tissue is often limited by cell and tissue expansion constraints, leading to stress and inflammatory responses. Adipose tissue remodeling in obesity involves dynamic changes in adipocyte number and size, with hypertrophy promoting IR and metabolic disease. Adipose tissue dysfunction is associated with increased visceral and ectopic fat accumulation, and metabolic complications. Adipocyte commitment and terminal differentiation are regulated by various signaling pathways, including WNT and BMP4, which are crucial for adipogenesis. Impaired adipogenesis in obesity leads to reduced adipocyte function and increased IR. Chronic inflammation in adipose tissue contributes to IR by promoting macrophage infiltration, hypoxia, and the release of inflammatory cytokines. Ectopic fat accumulation in organs like the liver, skeletal muscle, and heart leads to lipotoxicity, further exacerbating IR and metabolic complications. The mechanisms underlying these processes involve complex interactions between adipose tissue expansion, inflammation, and metabolic dysfunction. Understanding these mechanisms is essential for developing therapeutic strategies to combat obesity-associated metabolic complications.Adipose tissue dysfunction is a key determinant of obesity-associated metabolic complications. Obesity increases the risk of type 2 diabetes (T2D) and is associated with metabolic abnormalities such as insulin resistance (IR), dyslipidemia, non-alcoholic fatty liver disease (NAFLD), hypertension, and cardiovascular disease. White adipose tissue (WAT) plays a critical role in energy homeostasis, expanding through hypertrophy (increase in adipocyte size) and hyperplasia (increase in number). In metabolically unhealthy obesity, the storage capacity of subcutaneous adipose tissue (SAT) is limited, leading to ectopic lipid accumulation in organs like the liver, skeletal muscle, and heart, a process known as lipotoxicity. This results in local inflammation and systemic IR. Excessive ectopic lipid accumulation triggers chronic low-grade inflammation, which exacerbates IR and T2D. In obesity, "healthy" WAT expansion is achieved through adipocyte hyperplasia, while hypertrophy promotes metabolic complications. Adipose tissue dysfunction is linked to impaired adipogenesis, inflammation, and ectopic lipid deposition. In obesity, the expansion of adipose tissue is often limited by cell and tissue expansion constraints, leading to stress and inflammatory responses. Adipose tissue remodeling in obesity involves dynamic changes in adipocyte number and size, with hypertrophy promoting IR and metabolic disease. Adipose tissue dysfunction is associated with increased visceral and ectopic fat accumulation, and metabolic complications. Adipocyte commitment and terminal differentiation are regulated by various signaling pathways, including WNT and BMP4, which are crucial for adipogenesis. Impaired adipogenesis in obesity leads to reduced adipocyte function and increased IR. Chronic inflammation in adipose tissue contributes to IR by promoting macrophage infiltration, hypoxia, and the release of inflammatory cytokines. Ectopic fat accumulation in organs like the liver, skeletal muscle, and heart leads to lipotoxicity, further exacerbating IR and metabolic complications. The mechanisms underlying these processes involve complex interactions between adipose tissue expansion, inflammation, and metabolic dysfunction. Understanding these mechanisms is essential for developing therapeutic strategies to combat obesity-associated metabolic complications.